Lista de obras - Sabine Cerny-Reiterer - Dominio Público Uruguay

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

artículo científico publicado en 2012

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

artículo científico publicado en 2014

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL

artículo científico publicado en 2013

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

artículo científico publicado en 2010

Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils

artículo científico publicado en 2012

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

artículo científico publicado en 2011

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage

artículo científico publicado en 2014

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

artículo científico publicado en 2014

DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia

artículo científico publicado en 2014

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

artículo científico publicado en 2014

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm

artículo científico publicado en 2016

Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.

artículo científico publicado en 2009

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H

artículo científico publicado en 2013

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells

artículo científico publicado en 2017

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

artículo científico publicado en 2015

Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression

artículo científico publicado en 2012

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

artículo científico publicado en 2011

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

artículo científico publicado en 2009

Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice

artículo científico publicado en 2010

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

artículo científico publicado en 2011

Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.

artículo científico publicado en 2014

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

artículo científico publicado en 2016

Overexpression of primary microRNA 221/222 in acute myeloid leukemia

artículo científico publicado en 2013

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

artículo científico publicado en 2012

Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

artículo científico publicado en 2010

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

artículo científico publicado en 2010

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

artículo científico publicado en 2011

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

artículo científico publicado en 2012

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia

artículo científico publicado en 2012

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

artículo científico publicado en 2012

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS) ⬇️

artículo científico publicado el 1 de noviembre de 2010

Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation

artículo científico publicado en 2010

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

artículo científico publicado en 2011

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

artículo científico publicado en 2013

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

scientific article published on 14 September 2015

Lista de obras de Sabine Cerny-Reiterer

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm

Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

Overexpression of primary microRNA 221/222 in acute myeloid leukemia

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS) ⬇️

Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition